Skip to main content

Diagnostic innovations for critical care settings

Sometimes, in critically ill patients, the underlying pathomechanism behind the clinical symptoms is unclear. The research conducted at SphingoTec has identified key players involved in major pathways leading to mortality in critical care: bio-ADM relevant for shock resulting from endothelial dysfunction, penKid preventing delayed recognition of loss of kidney function and DPP3 release resulting from dysregulated cell death . Based on the highest standard of evidence, we have developed in vitro diagnostics for the diagnosis, prediction, and monitoring of these major mortality drivers. Blood-based measurement of our biomarkers allows tailored medicine and thereby improves patient management. Find out more about the critical care settings in which our biomarkers can complement the critical care diagnostics. 

Body of evidence for our biomarkers:

Sepsis and Septic Shock

Acute Kidney Injury

Renal Transplantation

Chronic Kidney Disease

Cardiogenic Shock

Acute Heart Failure

Acute Myocardial Infarction

Acute Coronary Syndrome

Intensive Care Unit (ICU)

Emergency Department (ED)

Major Surgery


Discover more on the clinical evidence

SphingoTec biomarker discovery is based on the highest standard of evidence, with over 100 publications, over 100 clinical studies, and more than 100.000 patients enrolled. To discover more on our clinical evidence, visit our publications page. 

Learn more